导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.89% | 2435/4773 |
| 近一周 | -2.18% | 1411/5462 |
| 近一月 | -4.06% | 2177/5421 |
| 近一季 | -6.84% | 2216/5209 |
| 近半年 | -1.79% | 1693/4920 |
| 近一年 | 2.20% | 2175/4366 |
| 近两年 | 47.87% | 1544/2954 |
| 近三年 | 30.14% | 1052/2253 |
| 成立以来 | 138.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.53% 3263/4961 |
12.63% 2149/5312 |
- - |
- - |
| 2025 | 20.42% 2122/4813 |
-0.90% 2451/3635 |
2.19% 1772/4076 |
17.99% 2377/4524 |
0.77% 1783/4813 |
| 2024 | 17.22% 713/3463 |
2.96% 653/2808 |
-1.16% 956/3014 |
16.59% 1411/3129 |
-1.20% 1624/3463 |
| 2023 | -8.83% 1064/2656 |
4.33% 981/2280 |
-3.79% 903/2385 |
-2.82% 758/2515 |
-6.53% 1815/2655 |
| 2022 | -18.92% 777/2207 |
-13.71% 822/1919 |
6.67% 641/2016 |
-13.50% 911/2113 |
1.83% 1123/2208 |
| 2021 | -3.09% 886/1822 |
-2.96% 733/1255 |
4.12% 920/1330 |
-5.65% 839/1466 |
1.65% 850/1822 |
| 2020 | 27.41% 581/1250 |
-9.62% 696/1028 |
12.92% 660/1067 |
10.52% 541/1164 |
12.96% 408/1184 |
| 2019 | 35.10% 383/1092 |
26.47% 408/754 |
-0.43% 262/804 |
0.46% 516/850 |
6.79% 548/918 |
| 2018 | -22.42% 239/834 |
- - |
- - |
- - |
-11.57% 318/691 |
| 2017 | 21.94% 157/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.13% 257/605 |
- - |
- - |
- - |
- - |
| 2015 | 6.03% 208/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.44% 73/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.18% 111/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.61% 51/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.53% 59/102 |
- - |
- - |
- - |
- - |
| 2010 | -11.77% 27/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银沪深300指数A VS. 长安沪深300非周期A(740101) |